The expression of MIF is associated with the clinical severity of various autoimmune diseases and is regulated by several key transcription factors such as ICBP90, Pit‐1, Sp1, and AP‐1.[44] Additionally, elevated Sp1 levels can lead to the degradation of p53 through MDM2‐mediated ubiquitination.[28a] Furthermore, TLR4 agonists have been shown to significantly increase MIF expression through ICBP90, prompting further investigation into the relationship between resistin and MIF. This evidence concerns the gene RETN and autoimmune disease.